Please login to the form below

Not currently logged in

CHMP recommends marketing authorisation for AZ’s Evusheld in the EU

The treatment can be used to prevent people contracting COVID-19 and can be given to adults and children aged 12 years and older


AstraZeneca’s Evusheld, a long-acting antibody combination, has received a recommendation for marketing authorisation in the European Union (EU). The treatment – given as two intramuscular injections – is for the pre-exposure prevention of COVID-19, and can be given to adults and children aged 12 years and older.

The Committee for Medicinal Products for Human Use (CHMP) branch of the European Medicines Agency based its positive opinion on an evaluation of Evusheld data, which included results from the PROVENT phase 3 pre-exposure prevention trial.

The trial showed a 77% reduction in the risk of developing symptomatic COVID-19 compared to placebo. Additionally, it showed an 83% reduction at six months, with protection continuing for at least six months.

Those who are not protected by a COVID-19 vaccine – including around three million people living in the EU who are immunocompromised or being treated with immunosuppressive medicines – may benefit from pre-exposure prevention with Evusheld.

Mene Pangalos, executive vice president, BioPharmaceuticals R&D, AstraZeneca, said: “Evusheld has the potential to provide long-lasting protection to vulnerable populations such as the immunocompromised who can’t mount an adequate response to a COVID-19 vaccine, and we’ll continue to work with governments in Europe to make Evusheld available as quickly as possible.”

Hugh Montgomery, Professor of Intensive Care Medicine at University College London, UK and Evusheld investigator said: “Despite the success of vaccinations, we still need additional measures to prevent the spread of COVID-19 infections in Europe, where the number of cases of the highly transmissible BA.2 subvariant is rapidly increasing and where public health safety measures have been relaxed in many countries.

“This broad recommendation for Evusheld will allow health authorities in the EU to identify priority, high-risk populations needing additional protection such as people with cancer, transplant patients, or anyone taking immunosuppressive medicines, as well as those at increased risk of exposure.”

AZ has said it expects the European Commission will soon complete its review of the CHMP decision on whether to grant a marketing authorisation. Evusheld is authorised for emergency use for pre-exposure prevention of COVID-19 in the US and in six countries in Europe. The treatment has also been given a conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.

Article by
Fleur Jeffries

25th March 2022

From: Regulatory



Subscribe to our email news alerts


Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...